2024 ASCO® Annual Meeting Insights Hub
Meeting coverage & Vumedi’s exclusive highlights, all in one place.
ASCO® 2024 Insights: "Biomarker Analysis & Updated Clinical Outcomes - Neoadjuvant Systemic Treatment With Nivolumab and Relatlimab in Surgically Resectable Melanoma"
By
2024 ASCO® Annual Meeting Insights Hub
FEATURING
Liz Burton
By
2024 ASCO® Annual Meeting Insights Hub
FEATURING
Liz Burton
Login to view comments.
Click here to Login